MKI67 and neuroendocrine carcinoma: Everolimus was combinedwith cisplatin in a phase II, single-arm clinical trial in 39 participants withEP-PD-NEC (Table3).47 All patients had primary tumours of PD morphology andthe median Ki-67 index was 80%.